HER2+ 유방암

ADCBiologicstaleChipscreen Biosciences, Ltd.Phase 3

효능 ORR 34%임상시험 31상태 ACTIVE

taxane drug (taxane drug)

HER2-positive Metastatic Breast Cancer; First-line Treatment · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3

효능 ORR 81.1%임상시험 31상태 RECRUITING

AntibodystaleQuantumLeap Healthcare Collabor…Phase 2

AMG 479 (AMG 479, Ganitumab, AMG 479 (Ganitumab) plus Metformin)

Breast Neoplasms; Breast Cancer · HER2

ADCBiologicAstraZenecaderuxtecan and rilvegostomi…Phase 2

효능 ORR 27%임상시험 30상태 RECRUITING

Rilvegostomig (AZD8205 and AZD2936, AZD8205 and AZD2936 (Rilvegostomig))

Breast Cancer; Biliary Tract Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4

ADCBiologicstaleLaura Huppert, MD, BAPhase 2

Amiloride (Amiloride)

HER2 Low Breast Carcinoma; Triple Negative Breast Cancer · HER2

AntibodystaleRochePhase 3

trastuzumab (Herceptin, Docetaxel combined + Trastuzumab +Pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase3#항체#면역항체+2

효능 ORR 91.8%임상시험 30상태 RECRUITING

AntibodystaleRochePreclinical

trastuzumab (Herceptin, Docetaxel combined with Trastuzumab±Pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#항체#면역항체+2

효능 ORR 91.8%임상시험 30상태 ACTIVE

ADCBiologicstaleHoffmann-La RochePhase 2

Docetaxel or Nab-paclitaxel (Docetaxel or Nab-paclitaxel)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 23.1%임상시험 30상태 RECRUITING

AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab plus Olaparib)

Breast Neoplasms; Breast Cancer · HER2

ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

효능 ORR 55.1%임상시험 30상태 RECRUITING

Ganetespib (Ganetespib)

Breast Neoplasms; Breast Cancer · HER2

AntibodystaleRochePhase 2

효능 ORR 20%임상시험 30상태 RECRUITING

trastuzumab (Herceptin, HER2, pyrotinib + pertuzumab/trastuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

ADCBiologicstalePuma Biotechnology, Inc.Phase 2

HKI-272 (HKI-272)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 74.8%임상시험 30상태 ACTIVE

ADCBiologicstaleThe N.1 Institute for Health (N…Phase 2

Organoid-guided treatment (Organoid-guided treatment)

HER2-negative Breast Cancer; Advanced Breast Cancer · HER2

AntibodystaleRochePreclinical

trastuzumab (Herceptin, Pertuzumab Plus Trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#항체#면역항체+2

효능 ORR 69.3%임상시험 30상태 ACTIVE

AntibodystaleRochePreclinical

trastuzumab (Herceptin, Pyrotinib Plus Trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#항체#면역항체+2

임상시험 30상태 ACTIVE

ADCBiologicstaleZheng YabingPhase 2

Ribociclib Oral Tablet (Ribociclib Oral Tablet)

HER2-positive Advanced Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 66.1%임상시험 30상태 ACTIVE

ADCBiologicstaleRochePreclinical

ado-trastuzumab emtansine (Kadcyla, T-DM1, T-DM1 adjuvant)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+1

ADCBiologicstaleRochePhase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1, T-DM1 and Pertuzumab)

Breast Neoplasms; Breast Cancer · HER2